324 related articles for article (PubMed ID: 33529489)
21. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
22. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
Hocqueloux L; Raffi F; Prazuck T; Bernard L; Sunder S; Esnault JL; Rey D; Le Moal G; Roncato-Saberan M; André M; Billaud E; Valéry A; Avettand-Fènoël V; Parienti JJ; Allavena C;
Clin Infect Dis; 2019 Oct; 69(9):1498-1505. PubMed ID: 30601976
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study.
Pujari S; Gaikwad S; Panchawagh S; Chitalikar A; Joshi K; Rohekar C; Dabhade D; Bele V
AIDS Res Hum Retroviruses; 2024 Apr; 40(4):204-215. PubMed ID: 38063004
[TBL] [Abstract][Full Text] [Related]
24. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
25. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.
Palacios R; Gómez-Ayerbe C; Casado JL; Tejerina F; Montes ML; Castaño M; Ocampo A; Rial D; Ribera E; Galindo MJ; Hidalgo C; Fariñas C; Montero M; Payeras T; Fanjul F; de la Torre J; Santos J
HIV Med; 2023 Aug; 24(8):933-937. PubMed ID: 37016556
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
29. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
Dou Y; Lu R; Su L; Lan K; Meng Z; Qin S; Huang L; Huang W; Xu Y; Lv Y; Wen Y; Lan S; Zuo Y; Zhang Y
HIV Med; 2024 Jun; 25(6):754-758. PubMed ID: 38494173
[TBL] [Abstract][Full Text] [Related]
30. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
Deschanvres C; Reynes J; Lamaury I; Rey D; Palich R; Bani-Sadr F; Robineau O; Duvivier C; Hocqueloux L; Cuzin L; Joly V; Raffi F; Cabie A; Allavena C;
J Antimicrob Chemother; 2021 Dec; 77(1):196-204. PubMed ID: 34651192
[TBL] [Abstract][Full Text] [Related]
31. Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Bendala-Estrada AD; Diaz-Almiron M; Busca C; Mican R; Cadiñanos J; Montes ML; Martin-Carbonero L; Valencia E; Montejano R; Delgado-Hierro A; Bernardino JI
HIV Med; 2023 May; 24(5):558-567. PubMed ID: 36394195
[TBL] [Abstract][Full Text] [Related]
32. Safety and Effectiveness Analyses of Dolutegravir/Lamivudine in Patients with HIV: 2-Year Report of Post-Marketing Surveillance in Japan.
Tofukuji A; Hongo H; Nagao T; Sebata A; Suzuki M; Maeno Y; Kurosaki E; Fukuda A; Watanabe T
Adv Ther; 2023 Apr; 40(4):1884-1898. PubMed ID: 36840899
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.
Mehta R; Lagishetty CV; Angelis K; Aylott A; Kahl L; Blair L; Matthews J; Wynne B; Crauwels H; Underwood M; Adkison KK
Br J Clin Pharmacol; 2023 Jul; 89(7):2190-2200. PubMed ID: 36740580
[TBL] [Abstract][Full Text] [Related]
34. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
Ashta KK; Arora S; Khanna R; Raman N; Anilkumar A; Mohan C
Curr HIV Res; 2024; 22(1):31-46. PubMed ID: 38284697
[TBL] [Abstract][Full Text] [Related]
35. Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G; Assoumou L; de Castro N; Post FA; Curran A; Rusconi S; De Wit S; Stephan C; Raffi F; Johnson M; Masia M; Vera J; Jones B; Grove R; Fletcher C; Duffy A; Morris K; Pozniak A;
Lancet HIV; 2024 Mar; 11(3):e156-e166. PubMed ID: 38417976
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM; Brites C; Cheng CY; Osiyemi O; Galera C; Hocqueloux L; Maggiolo F; Degen O; Taylor S; Blair E; Man C; Wynne B; Oyee J; Underwood M; Curtis L; Bontempo G; van Wyk J
Clin Infect Dis; 2023 Feb; 76(4):720-729. PubMed ID: 35235656
[TBL] [Abstract][Full Text] [Related]
37. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.
Hidalgo-Tenorio C; Vinuesa D; García-Vallecillos C; Muñoz-Medina L; Sequera S; Javier R; López-Ruz MÁ; Sadyrbaeva-Dolgova S; Pasquau J
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560630
[TBL] [Abstract][Full Text] [Related]
38. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
39. Lamivudine plus dolutegravir as a switch strategy in children: three case reports.
Labate L; Bartalucci C; Taramasso L; Brucci G; Vena A; Bassetti M; Di Biagio A
New Microbiol; 2024 May; 47(1):111-115. PubMed ID: 38700892
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1-infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER study).
Lemaitre F; Lagoutte-Renosi J; Gagnieu MC; Parant F; Venisse N; Grégoire M; Bouchet S; Garraffo R; Lê MP; Muret P; Comets E; Solas C; Peytavin G;
Br J Clin Pharmacol; 2024 Jan; 90(1):264-273. PubMed ID: 37602480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
